Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering and developing first-in-class drugs that target microRNAs to treat various diseases.
| Website: | www.regulusrx.com |
| Email: | information@regulusrx.com |
| Main Phone: | +1 858 202-6300 |
| Address: | 3545 John Hopkins Court |
| Address 2: | Suite 210 |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92121 |
| Exchange: | NSD |
| Employees: | 94 |
| NAICS: | Pharmaceutical P |
| Last Price 1.05 | Change $ 0.03 | Change % 2.94 | Tick N/A |
| Bid 0.91 | Bid Size 2,000.00 | Ask 1.30 | Ask Size 5,000.00 |
| Open 1.02 | High 1.13 | Low 1.01 | Prev Close 1.02 |
| Last Trade | Volume 621,683 | 52 Wk Hi 4.25 | 52 Wk Low 0.86 |
| Market Cap 55.8 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 53,182,330.00 | EPS (TTM) -1.53 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 1 |
| Number of Buys | 0 | 1 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 10000 |
| Last 10 Buys | Shares |
|---|---|
| Joseph P. Hagan | 1,000 |
| Mark G. Foletta | 1,000 |
| William H. Rastetter | 1,000 |
| William H. Rastetter | 1,000 |
| Stanley T. Crooke | 1,000 |
| B. Lynne Parshall | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Bruce L.A. Carter | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 15 | 15 | 15 | 15 |
| Low Target Price Estimate | 4 | 4 | 4 | 4 |
| Mean Target Price Estimate | 10 | 10 | 10 | 10 |
| Standard Deviation | 4.06 | 4.06 | 4.06 | 4.06 |
| Date of Most Recent Estimate | 08/03/16 | 08/03/16 | 07/25/16 | 08/23/16 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 10-Q | Quarterly report with a continuing view of a company's financial position | 110 | 2016-08-03 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2016-08-02 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2016-06-27 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2016-06-23 |
| 8-K/A | Amendment to a previously filed 8-K | 3 | 2016-06-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 29 | 2016-06-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2016-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-03 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 7 |
| Moderate Buy | 1 | 1 | 0 | 0 |
| Hold | 1 | 1 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.43 | 1.43 | 1 | 1 |
© 2017 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
